首页> 美国卫生研究院文献>other >Identification of miRNAs Differentially Expressed in Clinical Stages of Human Colorectal Carcinoma—An Investigation in Guangzhou China
【2h】

Identification of miRNAs Differentially Expressed in Clinical Stages of Human Colorectal Carcinoma—An Investigation in Guangzhou China

机译:人大肠癌临床分期差异表达的miRNAs的鉴定—广州市的调查

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aberrant expression of microRNAs (miRNAs) has been implicated in human cancer, including colorectal cancer (CRC). Such dysregulated miRNAs may have potential as diagnostic markers or therapeutic targets. However, the nature of an association between these miRNAs and clinical stages of CRC is still not clear. To this end, we performed a miRNA profiling of 1547 distinct human miRNAs using 31 samples of tumor and paired normal mucosa obtained from 31 CRC patients. Based on statistical analyses of profiling data, we identified 569 miRNAs that were significantly dysregulated in CRC relative to normal tissues (P<0.05). Among the 569 dysregulated miRNAs, downregulation of 17 was associated with stages II, III, and IV colon and rectal cancers (separate or combined), according to our criteria. We also assessed the potential of these dysregulated miRNAs as diagnostic biomarkers for CRC patients who were without metastasis, and the value of the dysregulated miRNAs for predicting metastasis, lymph node and distant. Their distinct expression patterns in colon and rectal cancers were also examined. Although our findings cannot be immediately applied toward clinical diagnosis, our new study model for determining and assessing the biomarker potential of dysregulated miRNAs should be useful in further research in detection of human CRC.
机译:microRNA(miRNA)的异常表达与人类癌症有关,包括结直肠癌(CRC)。此类失调的miRNA可能具有作为诊断标记或治疗靶标的潜力。但是,这些miRNA与CRC临床分期之间关联的性质仍不清楚。为此,我们使用31例肿瘤样本和从31例CRC患者获得的配对正常粘膜对1547种不同的人miRNA进行了miRNA分析。基于分析数据的统计分析,我们鉴定了569个相对于正常组织在CRC中显着失调的miRNA(P <0.05)。根据我们的标准,在569个失调的miRNA中,有17个的下调与II,III和IV期结肠癌和直肠癌(分离的或合并的)相关。我们还评估了这些失调的miRNA作为无转移的CRC患者的诊断生物标志物的潜力,以及失调的miRNA在预测转移,淋巴结和远处的价值。还检查了它们在结肠癌和直肠癌中的独特表达模式。尽管我们的发现不能立即应用于临床诊断,但我们用于确定和评估失调的miRNAs的生物标志物潜力的新研究模型应可用于进一步研究人类CRC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号